• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NovoCure launches 2 pediatric trials of TTFields

NovoCure launches 2 pediatric trials of TTFields

May 4, 2017 By Fink Densford

Novocure

NovoCure (NSDQ:NVCR) said today it is launching 2 pilot trials exploring the use of tumor treating fields to treat pediatric patients with high grade gliomas.

The St. Helier, N.J.-based company produces the Optune, a mobile device that delivers low-intensity, intermediate frequency, alternating electric fields, referred to as “tumor treating fields” to inhibit cancer cell replication and cause cancer cell death.

The 1st trial is being sponsored by the Pediatric Brain Tumor Consortium in collaboration with the National Cancer Institute and will study the feasibility of using TTFields on children with recurrent or progressive sptratentorial high-grade glioma and ependymoma. The 25-patient study will aim to assess patient compliance and treatment-related toxicities, as well as event-free survival.

The 2nd study looks to enroll 12 patients and will examine the safety, tolerability and preliminary efficacy of TTFields in treating pediatric patients with high-grade gliomas. The trial will have 2 cohorts, with 1 arm of children with recurrent high-grade gliomas treated with TTFields alone while the 2nd will receive combined treatment with temozolomide and bevacizumab for children with both newly diagnosed and recurrent gliomas.

“Although solid tumor cancers are generally rare in children, brain and spinal cord tumors are the third most common type of childhood cancer. In order to make a meaningful impact in the lives of these children, we need ongoing research to test the safety and feasibility of potential treatments. We are pleased to see trials testing TTFields in this underserved population,” Dr. Stewart Goldman of Chicago’s Ann & Robert H. Lurie Children Hospital said in a press release.

Last month, NovoCure saw shares rise after the medical device maker beat losses per share expectations on Wall Street with its 1st quarter earnings results.

Filed Under: Clinical Trials, Oncology Tagged With: NovoCure

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy